Transplantation has been the official ILTS journal since 2015, and is available free to all ILTS members. It has been a trusted source for extensive and timely coverage of the most important advances in transplantation for nearly 50 years, and is now much enhanced by ILTS-sponsored editorial and scientific contributions.  It hosts all official ILTS guidelines and consensus statements, and has ILTS-badged sections on liver clinical and liver basic science.

Congratulations to Dr. Jeremy Chapman and the editorial board of Transplantation Journal for the remarkable rise in the impact factor to an impressive 6.2! I would also like to acknowledge the dedicated ILTS members whose numerous outstanding papers have played a crucial role in this achievement. This success is a testament to the power of teamwork and collaboration within the transplantation community.

Already a member? You can visit your Journal Access page to access Transplantation online.

ILTS-SETH Oncology Recommendations available now!  

The January 2022 issue of Transplantation features the full text of the ILTS-SETH consensus conference recommendations in four authoritative papers. A summary of the purpose and methodology of this comprehensive review precedes these papers, as follows:

  • The ILTS-SETH Consensus Conference on Extrahepatic Cancer and Liver Transplantation: paving the way

This commentary provides an introductory summary of the purpose and methods of the ILTS-SETH guidelines on extra-hepatic cancer in liver transplant recipients.

  • Evaluation & management of liver transplant candidates with prior non-hepatic cancer

Waitlisting a patient with a prior history of cancer is always complex and specific to each individual but guidelines on the principles, processes and data are important to improve the outcome for eqch person.

  • Prevention and management of donor-transmitted cancer after liver transplantation

Preventing donor transmitted cancer requires careful approaches to donor risk assessment and is specific to each type and stage of donor cancer. These ILTS-SETH guidelines provide a substantial body of information and the guidance that clinicians need to advise on risk management for their patients awaiting a liver transplant.

  • De novo malignancy after liver transplantation – risk assessment, prevention and management guidance

Everything is different for a patient with cancer who has a transplant compared to someoine that doesn’t. Prevention, screening, prognosis and treatment are worlds apart. These comprehensive ILTS-SETH guidelines provide great advice on both unit policy development and for individual patient management.

  • Non-hepatic cancer in the pediatric liver transplant population

Young transplant recipients are at the greatest relative risk for developing Cancers compared to their age cohort peers without transplants. This ILTS-SETH guideline provides the most current and comprehensive accumulation of data and advice on these most complex of children. 

ILTS Liver Editorial Team

Executive Editor

  • Jean C. Emond, MD

Liver Deputy Editor Medical

  • Francois Durand, MD

Liver Deputy Editor Surgical

  • Peter Friend, PhD, MD, MA

Liver Deputy Editor Basic Science

  • Nancy Kwan Man, MBBS, PhD

Associate Editors

  • Albert Chan, MBBS, FRCS, FCSHK, FHKAM
  • Manuel Rodriguez Davalos, MD
  • Mary Amanda Dew, PhD
  • Susumu Eguchi, MD, PhD, FACS, FEBS
  • James Findlay, MD
  • Constantino Fondevila, MD, PhD
  • Tom Gallagher, MS, MCh, FEBS, FRCSI
  • Wayel Jassem, MD, PhD
  • Keri Lunsford, MD, PhD
  • Gavin Pettigrew, MB, ChB, MD, FRCS
  • Eberhard Renner, MD, FRCP
  • Erin Rubin, MD, FCAP
  • Faouzi Saliba, MD, PhD
  • Gonzalo Sapisochin, MD
  • Nazia Selzner, MD, PhD
  • Mary Ann Simpson, MD
  • Simone I Strasser, MBBS, MD, FRACP
  • Yasuhiko Sugawar, MD, PhD
  • Heidi Yeh, MD
  • Gebhard Wagener, MD
  • Gabriel Gondolesi, MD (Intestine Tx)
  • Valeria Mas, PhD, FAST (Basic Science)

Linked open access title: Transplantation® Direct

Transplantation Direct is an open access portal supporting rapid electronic publication of high-quality, peer-reviewed basic science and clinical research in transplantation. The journal has been made possible through the joint efforts of The Transplantation Society, its affiliated international Sections, ILTS, and the journal Transplantation. It features original scientific papers, key registry reports, abstracts from international meetings and state of the art educational content. The flexibility of multimedia electronic publishing, combined with high standards of peer review and outstanding editorial leadership, has created a powerful new resource in the field of transplantation. For more information about Transplantation Direct, please visit ‘About the Journal’.

Submitting a manuscript to Transplantation or Transplantation Direct

For general information please visit ‘Instructions for Authors’ . Authors can submit manuscripts to Transplantation via the Transplantation Editorial Manager page or to Transplantation Direct via the Transplantation Direct Editorial Manager page. Further instructions for authors wishing to submit articles can be found here. This page contains information on the different article types in the journal. More article types will be added to the page in the near future. Transplantation editors decide to publish an article within 21 days, giving authors a quick response to their submissions.

Transplantation App

The Transplantation app is available for iPad users and provides:

  • Easy-to-read, full-text articles that you can share via email or social media
  • The ability to store or delete downloaded issues
  • Speedy issue-browsing capability via Quick View
  • Quick scrolling through abstract summaries
  • Convenient notification when a new issue is available
  • Links to view supplemental material and browse the Transplantation archive

Transplantation print copies

Should you be interested in receiving hard copies of the journal Transplantation, please visit if you have an active ILTS membership or contact us at The price of 12 hard copies is 174 USD.

Note about OVID journal access: Members please note that access to the OVID platform is no longer available because of potential contractual issues encountered by Wiley, publisher of the platform journals. ILTS entered into the agreement with OVID in good faith, and regrets any misunderstanding between Wiley and its client specialist societies, whom we believed had consented to this initiative on the basis of appropriate remuneration. We apologise to ILTS members who planned to use the platform, and wish to confirm that access to Transplantation is not affected. A full refund of ILTS expenditure on OVID has been received, which will be used to support other member benefits.